Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

May 5, 2026 | Pharma, healthcare, patient access 

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

- PMLiVE

Inizio announced the official launch of its fully integrated, end-to-end Hub Services, a cornerstone of its market-leading Patient Solutions offering. Delivered by Inizio Engage, the Inizio business unit specializing in patient engagement and support, this next-generation solution addresses the growing complexity of patient access, reimbursement, and adherence, while enabling clients to partner with a more agile, strategic, and outcome-driven organization.

As life sciences organizations navigate an increasingly dynamic policy and payer landscape, and higher expectations from patients, the need for more connected, patient-centric support models has never been greater. “Inizio Engage’s evolved Hub Services introduces a next-generation approach, integrating human expertise, intelligent technology, and pharmacy capabilities, supported by advanced analytics to simplify and accelerate the path to therapy,” said Ryan Quigley, CEO, Inizio. “This launch represents another opportunity for Inizio to lead the way as the global Intelligent Commercialization partner, bringing together insight, innovation, and execution to deliver more coordinated, patient-centered solutions for our clients.”

Read full article here. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy…

Webcast: Understanding the Chronic Disease Patient Journey in Emerging Markets

In emerging markets where primary care systems do not exist, the patient is the only constant in the journey

PEGASUS JOINS ASHFIELD HEALTHCARE COMMUNICATIONS

Pegasus, one of the most successful integrated healthcare communications consultancies in the UK, has today announced it has been acquired by UDG Healthcare plc, a FTSE 250 listed international provider…

Living with Crohn’s Report

Are you looking for a deeper understanding of the emotional needs, behaviours and treatment programmes of patients living with Crohn’s Disease?

Infographic: Research Partnership

Our latest infographic offers an overview of some key facts and figures about the company, its services and capabilities.

AAD conference 2016

Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Case study: Understanding Patient Willingness to Pay in Emerging Markets

Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out…

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016

Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers…